Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Current Deferred Revenue (2018 - 2024)

Historic Current Deferred Revenue for Dna X (SONM) over the last 7 years, with Q2 2024 value amounting to $12000.0.

  • Dna X's Current Deferred Revenue changed N/A to $12000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $12000.0, marking a year-over-year change of. This contributed to the annual value of $12000.0 for FY2023, which is 6129.03% down from last year.
  • Latest data reveals that Dna X reported Current Deferred Revenue of $12000.0 as of Q2 2024.
  • In the past 5 years, Dna X's Current Deferred Revenue ranged from a high of $872000.0 in Q2 2021 and a low of $3000.0 during Q1 2023
  • In the last 5 years, Dna X's Current Deferred Revenue had a median value of $31000.0 in 2022 and averaged $166933.3.
  • Per our database at Business Quant, Dna X's Current Deferred Revenue plummeted by 9828.18% in 2020 and then soared by 30000.0% in 2024.
  • Over the past 5 years, Dna X's Current Deferred Revenue (Quarter) stood at $5000.0 in 2020, then soared by 120.0% to $11000.0 in 2021, then skyrocketed by 181.82% to $31000.0 in 2022, then crashed by 61.29% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024.
  • Its Current Deferred Revenue stands at $12000.0 for Q2 2024, versus $12000.0 for Q1 2024 and $12000.0 for Q4 2023.